Arrowstreet Capital, Limited Partnership Genmab A/S Transaction History

Arrowstreet Capital, Limited Partnership

$136 Billion
Q2 2025

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Genmab A/S stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 3,454,378 shares of GMAB stock, worth $75.5 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

3,454,378

Previous 1,369,412 152.25%

Holding current value

$75.5 Million

Previous $26.8 Million 166.17%

% of portfolio

0.05%

Previous 0.02%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$17.98 - $23.09 $37.5 Million - $48.1 Million	2,084,966 Added 152.25%	3,454,378 $71.4 Million
Q1 2025 May 14, 2025	BUY	$18.69 - $24.14 $25 Million - $32.3 Million	1,338,972 Added 4398.73%	1,369,412 $26.8 Million
Q4 2024 Feb 12, 2025	SELL	$20.02 - $24.15 $1.27 Million - $1.53 Million	-63,188 Reduced 67.49%	30,440 $635,000
Q3 2024 Nov 14, 2024	BUY	$23.84 - $28.48 $1.34 Million - $1.6 Million	56,219 Added 150.28%	93,628 $2.28 Million
Q2 2024 Aug 14, 2024	BUY	$25.13 - $30.27 $940,088 - $1.13 Million	37,409 New	37,409 $940,000
Q1 2023 May 15, 2023	SELL	$34.88 - $43.22 $25.8 Million - $32 Million	-740,684 Reduced 42.2%	1,014,533 $38.3 Million
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $9.12 Million - $12.7 Million	269,691 Added 18.15%	1,755,217 $74.4 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $6.01 Million - $71.3 Million	190,807 Added 14.74%	1,485,526 $47.7 Million
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $11.4 Million - $16.4 Million	425,498 Added 48.95%	1,294,719 $42.1 Million
Q1 2022 May 13, 2022	BUY	$30.95 - $39.68 $10.5 Million - $13.4 Million	338,902 Added 63.91%	869,221 $31.4 Million
Q4 2021 Feb 14, 2022	BUY	$35.87 - $47.12 $3.68 Million - $4.84 Million	102,620 Added 23.99%	530,319 $21 Million
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $17.4 Million - $20.4 Million	418,099 Added 4355.2%	427,699 $18.7 Million
Q2 2021 Aug 13, 2021	SELL	$32.88 - $44.57 $2.96 Million - $4.01 Million	-90,033 Reduced 90.36%	9,600 $392,000
Q1 2021 May 14, 2021	SELL	$30.92 - $44.4 $8.85 Million - $12.7 Million	-286,067 Reduced 74.17%	99,633 $3.27 Million
Q4 2020 Feb 12, 2021	SELL	$33.66 - $40.76 $3.16 Million - $3.83 Million	-93,895 Reduced 19.58%	385,700 $15.7 Million
Q3 2020 Nov 12, 2020	SELL	$33.07 - $38.68 $8.27 Million - $9.68 Million	-250,174 Reduced 34.28%	479,595 $17.6 Million
Q2 2020 Aug 12, 2020	BUY	$20.05 - $33.89 $1.03 Million - $1.74 Million	51,467 Added 7.59%	729,769 $24.7 Million
Q1 2020 May 15, 2020	BUY	$17.15 - $25.22 $5.64 Million - $8.29 Million	328,880 Added 94.12%	678,302 $14.4 Million
Q4 2019 Feb 13, 2020	BUY	$18.88 - $24.14 $4.61 Million - $5.9 Million	244,317 Added 232.45%	349,422 $7.8 Million
Q3 2019 Nov 14, 2019	BUY	$18.0 - $21.38 $1.89 Million - $2.25 Million	105,105 New	105,105 $2.13 Million

Others Institutions Holding GMAB

# of Institutions

242

Shares Held

65M

Call Options Held

32.5K

Put Options Held

88.6K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.4B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account

Arrowstreet Capital, Limited Partnership Genmab A/S Transaction History